Cholecalciferol supplementation increases FGF23 in peritoneal dialysis patients with hypovitaminosis D: a randomized clinical trial.

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc in this randomized controlled trial publication.

Who Took Part

PubMed indexes the participants as adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.

Neither the participants nor the staff measuring them knew who was on Vitamin D, K2, Magnesium and Zinc, so expectations could not easily colour the readings.

The comparison arm used a placebo, so changes seen with Vitamin D, K2, Magnesium and Zinc could be set against what happens without it.

Double-blind, placebo-controlled, randomized clinical trial.

The outcome measures were the effects on the osteogenic biomarkers osteoprotegerin (primary endpoint), intact fibroblast growth factor-23 (iFGF23), osteocalcin, osteopontin, iPTH, 1,25-dyhydroxivitamin D (1,25D), and interleukin-6.

What Was Measured

Topics PubMed links to this paper include Biomarkers, Carotid Intima-Media Thickness, Cholecalciferol, Dietary Supplements, Fibroblast Growth Factor-23, Fibroblast Growth Factors and Interleukin-6.

The authors tagged it with the keywords 25-hydroxi vitamin D, Dialysis, End stage renal disease, Osteoprotegerin and Vitamin D.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc.

Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2019 (Journal of nephrology), a journal based in Italy.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.